The cohort study, involving 340 participants and lasting five years, reported that using a DPP-4 inhibitor was linked with a decreased risk of fractures due to any cause and fracture of the upper limbs in patients suffering from type 2 diabetes mellitus [67]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.